Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ANAB – AnaptysBio Inc

AnaptysBio, Inc.
ANAB
$23.38
Name : AnaptysBio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $686,916,096.00
EPSttm : -4.76
finviz dynamic chart for ANAB
AnaptysBio, Inc.
$23.38
10.60%
$2.24

Float Short %

33.35

Margin Of Safety %

Put/Call OI Ratio

1

EPS Next Q Diff

-0.28

EPS Last/This Y

-0.56

EPS This/Next Y

0.79

Price

21.14

Target Price

42.55

Analyst Recom

1.33

Performance Q

28.9

Relative Volume

1.56

Beta

-0.26

Ticker: ANAB




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07ANAB19.611.001.595728
2025-05-08ANAB19.531.000.685766
2025-05-09ANAB19.591.000.005776
2025-05-12ANAB20.071.000.035777
2025-05-13ANAB20.541.010.465765
2025-05-14ANAB19.431.003.505767
2025-05-15ANAB20.391.010.055791
2025-05-16ANAB20.241.011.255793
2025-05-19ANAB20.420.160.421574
2025-05-20ANAB21.090.185.001742
2025-05-21ANAB20.780.20999.991781
2025-05-22ANAB20.580.2228.001812
2025-05-23ANAB20.430.2418.251841
2025-05-27ANAB20.150.2911.181932
2025-05-28ANAB20.660.451.062206
2025-05-29ANAB22.560.9018.4110475
2025-05-30ANAB22.471.052.0611372
2025-06-02ANAB21.831.060.0311434
2025-06-03ANAB23.541.004.1311802
2025-06-04ANAB21.250.980.6312001
2025-06-05ANAB21.181.001.3212086
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07ANAB19.6810.8-1.0-5.30
2025-05-08ANAB19.582.6-11.9-5.95
2025-05-09ANAB19.592.6-29.6-5.95
2025-05-12ANAB20.032.6-35.0-5.95
2025-05-13ANAB20.542.6-35.5-5.95
2025-05-14ANAB19.452.6-17.1-5.95
2025-05-15ANAB20.442.6-42.1-5.95
2025-05-16ANAB20.242.6-27.1-5.95
2025-05-19ANAB20.472.6-32.5-5.95
2025-05-20ANAB21.092.6-36.5-5.95
2025-05-21ANAB20.782.6-25.8-5.95
2025-05-22ANAB20.732.6-28.6-5.95
2025-05-23ANAB20.408.4-25.6-5.68
2025-05-27ANAB20.138.4-25.8-5.68
2025-05-28ANAB20.888.4-38.3-5.68
2025-05-29ANAB22.568.4-47.8-5.68
2025-05-30ANAB22.238.4-26.2-5.68
2025-06-02ANAB21.838.4-25.6-5.68
2025-06-03ANAB23.528.4-46.1-5.68
2025-06-04ANAB21.288.4-10.1-5.68
2025-06-05ANAB21.148.4-27.9-5.68
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07ANAB3.4110.1638.06
2025-05-08ANAB3.4110.1638.06
2025-05-09ANAB3.4110.1639.73
2025-05-12ANAB3.417.0933.07
2025-05-13ANAB3.417.0933.07
2025-05-14ANAB3.417.0933.07
2025-05-15ANAB3.417.0933.07
2025-05-16ANAB3.417.0933.07
2025-05-19ANAB3.4116.7533.85
2025-05-20ANAB2.6616.7533.85
2025-05-21ANAB2.6616.7533.85
2025-05-22ANAB2.6616.7533.85
2025-05-23ANAB2.6616.7533.85
2025-05-27ANAB2.6625.5733.85
2025-05-28ANAB2.6625.5733.35
2025-05-29ANAB2.6625.5733.35
2025-05-30ANAB2.6625.5733.35
2025-06-02ANAB2.6625.9933.35
2025-06-03ANAB2.6625.9933.35
2025-06-04ANAB3.0225.9933.35
2025-06-05ANAB3.0225.9933.35
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.28

Avg. EPS Est. Current Quarter

-1.57

Avg. EPS Est. Next Quarter

-1.56

Insider Transactions

3.02

Institutional Transactions

25.99

Beta

-0.26

Average Sales Estimate Current Quarter

11

Average Sales Estimate Next Quarter

12

Fair Value

Quality Score

24

Growth Score

54

Sentiment Score

82

Actual DrawDown %

48.8

Max Drawdown 5-Year %

-69.3

Target Price

42.55

P/E

Forward P/E

PEG

P/S

5.55

P/B

18.88

P/Free Cash Flow

EPS

-4.84

Average EPS Est. Cur. Y​

-5.68

EPS Next Y. (Est.)

-4.89

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-125.7

Relative Volume

1.56

Return on Equity vs Sector %

-437.3

Return on Equity vs Industry %

-419.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.38

EBIT Estimation

-27.9
AnaptysBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 136
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
stock quote shares ANAB – AnaptysBio Inc Stock Price stock today
news today ANAB – AnaptysBio Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANAB – AnaptysBio Inc yahoo finance google finance
stock history ANAB – AnaptysBio Inc invest stock market
stock prices ANAB premarket after hours
ticker ANAB fair value insiders trading